Rob is Head of Business Development, North America, for GlueTacs Therapeutics. Previously, he worked in corporate and business development at Rakuten Medical, developing drug-device (photoimmunotherapy) oncology treatments. Prior to that, he worked at Fannin Innovation Studio, a venture creation firm, where he co-founded Goldenrod Therapeutics (anti-neuroinflammatory) and supported multiple portfolio programs across a variety of indications. He began his career in technology transfer at the National Cancer Institute, having earned his PhD from the University of North Carolina at Chapel Hill.